High-Versus Low-dose Angiotensin Converting Enzyme Inhibitor Therapy in the Treatment of Heart Failure: An Economic Analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial

Author(s)J. Sanford Schwartz, MD, Y. Richard Wang, MD, PhD, John G. F. Cleland, MD

Download PDF: High-Versus Low-dose Angiotensin Converting Enzyme Inhibitor Therapy in the Treatment of Heart Failure: An Economic Analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial

Articles in this issue

about 23 years ago

Article

A Randomized Trial of an Acid-peptic Disease Management Program in a Managed Care Environment

about 23 years ago

Article

When Money Is Saved by Reducing Healthcare Costs, Where Do US Primary Care Physicians Think the Money Goes?

about 23 years ago

Article

Care Management Interventions for Older Patients with Congestive Heart Failure

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

High-Versus Low-dose Angiotensin Converting Enzyme Inhibitor Therapy in the Treatment of Heart Failure: An Economic Analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

Medicaid MFN Pricing Could Save $8.6 Billion

CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks

Cardiology Prices Vary Widely by Insurer and State

Active US Drug Shortages Rise for Third Straight Quarter

Early-Onset CKD Mortality Declines Globally as Incidence Continues to Rise